Mischa Reis Sells 9,675 Shares of Envista (NYSE:NVST) Stock

Envista Holdings Corporation (NYSE:NVST) SVP Mischa Reis sold 9,675 shares of the firm’s stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $30.00, for a total value of $290,250.00. Following the sale, the senior vice president directly owned 32,382 shares of the company’s stock, valued at $971,460. The trade was a 23.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Envista Stock Performance

NYSE:NVST opened at $28.73 on Friday. The stock has a market capitalization of $4.72 billion, a P/E ratio of 102.61, a PEG ratio of 2.07 and a beta of 1.01. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.04 and a current ratio of 2.38. Envista Holdings Corporation has a fifty-two week low of $14.22 and a fifty-two week high of $30.42. The company has a 50 day moving average price of $23.54 and a 200 day moving average price of $21.48.

Envista (NYSE:NVST) last released its quarterly earnings results on Thursday, February 5th. The company reported $0.38 EPS for the quarter, topping the consensus estimate of $0.32 by $0.06. Envista had a return on equity of 6.54% and a net margin of 1.73%.During the same quarter last year, the company earned $0.24 earnings per share. The business’s revenue for the quarter was up 15.0% on a year-over-year basis. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. Equities research analysts forecast that Envista Holdings Corporation will post 1 EPS for the current year.

Key Envista News

Here are the key news stories impacting Envista this week:

• Positive Sentiment: Q4 EPS and revenue beat drove early upside — Zacks reports NVST jumped after the quarter as EPS and revenue topped expectations and segments showed double-digit growth despite margin pressure. Read More.
• Positive Sentiment: Barclays raised its price target to $34 and moved the stock to “overweight,” giving Wall Street momentum and a stronger institutional narrative behind the rally. Read More.
• Positive Sentiment: Broker recognition: NVST was added to Zacks’ top growth list (Zacks Rank #1), which can attract momentum and growth-focused flows. Read More.
• Neutral Sentiment: Mizuho nudged its target higher to $27 but kept a neutral rating — a modest endorsement that is less bullish than some peers and may temper further upside. Read More.
• Negative Sentiment: Underlying profitability concerns: a Quiver summary shows Q4 revenue grew modestly, but Envista reported a large operating loss (~$337M) and net loss (~$372M), which weighs on the sustainability of the EPS beat and investor confidence. Cash remains healthy, but the losses are a material negative. Read More.
• Negative Sentiment: Insider and institutional selling: SVP Mischa Reis disclosed a sale (~9,675 shares) and major funds have trimmed stakes recently (e.g., Morgan Stanley, BlackRock, Point72), which can pressure the stock and prompt profit-taking. Read More. • Read More.

Analyst Ratings Changes

A number of brokerages recently issued reports on NVST. Leerink Partners set a $35.00 price target on shares of Envista and gave the stock an “outperform” rating in a research note on Friday, February 6th. Mizuho increased their target price on shares of Envista from $24.00 to $27.00 and gave the stock a “neutral” rating in a research note on Tuesday. UBS Group boosted their price objective on shares of Envista from $22.00 to $25.00 and gave the company a “neutral” rating in a research note on Tuesday, February 3rd. Wells Fargo & Company increased their target price on Envista from $21.00 to $26.00 and gave the stock an “equal weight” rating in a research note on Friday, February 6th. Finally, Morgan Stanley set a $19.00 price objective on shares of Envista in a research note on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Envista currently has an average rating of “Moderate Buy” and a consensus price target of $27.43.

Institutional Trading of Envista

Institutional investors have recently made changes to their positions in the stock. Farther Finance Advisors LLC grew its holdings in shares of Envista by 317.6% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,349 shares of the company’s stock worth $27,000 after purchasing an additional 1,026 shares during the period. Caitong International Asset Management Co. Ltd lifted its holdings in Envista by 16,711.1% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 1,513 shares of the company’s stock worth $31,000 after buying an additional 1,504 shares in the last quarter. Allworth Financial LP boosted its holdings in Envista by 75.4% in the fourth quarter. Allworth Financial LP now owns 1,805 shares of the company’s stock valued at $39,000 after purchasing an additional 776 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Envista by 73.1% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,248 shares of the company’s stock worth $44,000 after buying an additional 949 shares in the last quarter. Finally, IFP Advisors Inc increased its position in shares of Envista by 102.9% in the 4th quarter. IFP Advisors Inc now owns 2,112 shares of the company’s stock worth $46,000 after purchasing an additional 1,071 shares during the last quarter.

About Envista

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.